RSS

epidermolysis bullosa

Abeona Therapeutics, a clinical-stage biopharmaceutical company, has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its for its gene therapy in epidermolysis bullosa in EB-101. more

News